Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases by eurofever registry and the Pediatric Rheumatology international Trial Organization (PRinTO)
  1405Ter Haar NM, et al. Ann Rheum Dis 2019;78:1405–1411. doi:10.1136/annrheumdis-2018-214472
Autoinflammatory disorders
CliniCal sCienCe
Clinical characteristics and genetic analyses of 187 
patients with undefined autoinflammatory diseases
nienke M Ter Haar,1,2 Charlotte eijkelboom,   2,3 luca Cantarini,4 Riccardo Papa,5 
Paul a Brogan,6 isabelle Kone-Paut,7 Consuelo Modesto,8 Michael Hofer,9 
nicolae iagaru,10 sárka Fingerhutová,11 antonella insalaco,12 Francesco licciardi,13 
Yosef Uziel,14 Marija Jelusic,   15 irina nikishina,16 susan nielsen,17 
efimia Papadopoulou-alataki,18 alma nunzia Olivieri,19 Rolando Cimaz,20 
Gordana susic,21 Valda stanevica,22 Marielle van Gijn,23 antonio Vitale,4 
nicolino Ruperto,24 Joost Frenkel,3 Marco Gattorno,   24 eurofever registry and the 
Pediatric Rheumatology international Trial Organization (PRinTO)
To cite: Ter Haar nM, 
eijkelboom C, Cantarini l, 
et al. Ann Rheum Dis 
2019;78:1405–1411.
Handling editor Prof Josef s 
smolen
 ► additional material is 
published online only. To 
view please visit the journal 
online (http:// dx. doi. org/ 10. 
1136annrheumdis- 2018- 
214472).
For numbered affiliations see 
end of article.
Correspondence to
Prof Dr Joost Frenkel;  
 j. frenkel@ umcutrecht. nl
Dr Marco Gattorno;  
 marcogattorno@ gaslini. org
nMTH and Ce are joint first 
authors.
JF and MGare joint senior 
authors.
Received 21 september 2018
Revised 3 June 2019
accepted 3 June 2019
Published Online First 
5 July 2019
© author(s) (or their 
employer(s)) 2019. no 
commercial re-use. see rights 
and permissions. Published 
by BMJ.
AbsTrACT
Objectives To describe the clinical characteristics, 
treatment response and genetic findings in a large cohort 
of patients with undefined systemic autoinflammatory 
diseases (saiDs).
Methods Clinical and genetic data from patients with 
undefined saiDs were extracted from the eurofever 
registry, an international web-based registry that 
retrospectively collects clinical information on patients 
with autoinflammatory diseases.
results This study included 187 patients. seven 
patients had a chronic disease course, 180 patients 
had a recurrent disease course. The median age at 
disease onset was 4.3 years. Patients had a median of 
12 episodes per year, with a median duration of 4 days. 
Most commonly reported symptoms were arthralgia 
(n=113), myalgia (n=86), abdominal pain (n=89), 
fatigue (n=111), malaise (n=104) and mucocutaneous 
manifestations (n=128). in 24 patients, relatives were 
affected as well. in 15 patients, genetic variants were 
found in autoinflammatory genes. Patients with genetic 
variants more often had affected relatives compared 
with patients without genetic variants (p=0.005). 
Most patients responded well to non-steroidal 
anti-inflammatory drugs (nsaiDs), corticosteroids, 
colchicine and anakinra. Complete remission was rarely 
achieved with nsaiDs alone. notable patterns were 
found in patients with distinctive symptoms. Patients 
with pericarditis (n=11) were older at disease onset 
(33.8 years) and had fewer episodes per year (3.0/
year) compared with other patients. Patients with an 
intellectual impairment (n=8) were younger at disease 
onset (2.2 years) and often had relatives affected 
(28.6%).
Conclusion This study describes the clinical 
characteristics of a large cohort of patients with 
undefined saiDs. among these, patients with pericarditis 
and intellectual impairment appear to comprise distinct 
subsets.
InTrOduCTIOn
One of the most frequently observed groups in 
autoinflammatory disease clinics are patients with 
undefined systemic autoinflammatory diseases 
(SAIDs).1 2 Providing targeted treatment for these 
patients is difficult, since a definite diagnosis is 
lacking. Little is known about the clinical and 
genetic characteristics of these patients, which 
impedes the identification of novel clusters within 
this group. This study provides insight into the clin-
ical picture of a large group of patients with unde-
fined SAIDs.
SAIDs are disorders characterised by periodic or 
persistent activation of the innate immune system 
in the absence of infection or autoimmunity. In 
monogenic SAIDs, this is caused by mutations 
in a single gene.3 The best-characterised mono-
genic SAIDs are familial Mediterranean fever 
(FMF), cryopyrin-associated periodic syndromes 
(CAPS), tumour necrosis factor-receptor-associ-
ated periodic syndrome (TRAPS) and mevalonate 
kinase deficiency (MKD).4 5 Other SAIDs, such as 
periodic fever, aphthous stomatitis, pharyngitis, 
adenitis (PFAPA) syndrome or Behҫet’s disease, are 
Key messages
What is already known about this subject?
 ► Individuals with undefined autoinflammatory 
diseases represent the majority of 
patients approaching the services devoted 
to the diagnosis and management of 
autoinflammatory diseases.
What does this study add?
 ► This study provides a detailed description of 
the clinical characteristics of a large cohort 
of patients with undefined autoinflammatory 
diseases, along with known genetic data and 
response to treatment.
How might this impact on clinical practice or 
future developments?
 ► The detailed description of patients with specific 
symptoms can be used to identify similar 
patients in other centres and will aid future 
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multifactorial; multiple genes may be involved, but there is no 
single genetic cause. Clinical diagnostic criteria are available for 
these diseases.6 7 However, approximately half of the patients 
with recurrent inflammation do not fit the clinical picture of any 
well-defined SAID or do not have pathogenic mutations causing 
a known hereditary SAID.1 2 This group is said to have ‘unde-
fined SAIDs’.
Characteristics of patients with undefined SAIDs have not 
been extensively described in the current literature. This might 
be due to the rarity of SAIDs, hampering sufficient patient 
numbers for research. To overcome this problem, an interna-
tional network for the study of SAIDs was established, the Euro-
fever Project.8 9 Besides the well-defined SAIDs, the Eurofever 
Project also collects clinical information on patients with unde-
fined SAIDs, providing a sufficient cohort for our study.
This paper describes the clinical characteristics of a large 
cohort of patients with undefined SAIDs, along with known 
genetic data and response to treatment.
MeTHOds
eurofever registry
Data of patients with undefined SAIDs were collected from the 
Eurofever registry (Executive Agency for Health and Consumers 
project no. 2007332), which has been collecting retrospective 
patient data since November 2009.9 Data entered before 2 
November 2016 were extracted. To enrol patients as undefined 
SAID in the registry, other confounding conditions (well-defined 
SAIDs including PFAPA syndrome, infectious, autoimmune, 
neoplastic) should have been reasonably excluded.
Ethical committee approval and informed consent was 
obtained in all participating centres. Detailed epidemiological, 
demographic and clinical data were collected anonymously.
Inclusion and exclusion criteria
Patients of whom clinical information was available were 
included in this study. The exclusion process consisted of two 
steps. First, patients were excluded from analysis if there was no 
evidence of increased acute phase reactants during episodes, if 
there was no fever reported or if they carried pathogenic muta-
tions classifying them as having a well-defined SAID.
Second, the Federici criteria were retrospectively applied on 
the cohort. The Federici criteria are clinical criteria for well-de-
fined monogenetic SAIDs.10 Additional data were collected from 
patients with a clinical picture consistent with a defined SAID, 
but without genetic analysis performed on the associated gene.10 
Centres were asked if additional genetic analysis was performed 
since registration. Subsequently, patients were excluded from 
analysis if further genetic analysis revealed a defined SAID, if 
they received a different diagnosis explaining their symptoms or 
if no additional genetic analysis was performed.
Clinical and genetic information
The clinical characteristics included the disease pattern, disease 
manifestations and response to treatment. Clinical manifesta-
tions were reported by the entering physician as being present 
never, sometimes/often or always during episodes. Treatment 
response was graded as complete (absence of clinical manifes-
tations with normalisation of inflammatory markers), partial 
(general amelioration of the clinical picture but not complete 
normalisation of the clinical manifestations and/or systemic 
inflammation) or failure (lack of response). Information on 
molecular genetic analyses regarding the main SAIDs was 
collected. Genetic variants were classified as being pathogenic, 
likely pathogenic, of uncertain significance, likely benign or 
benign.11 12 Only pathogenic or likely pathogenic variants and 
variants of uncertain significance were noted in this study and 
were regarded as genetic variants in further analyses.13
statistical analysis
Categorical variables were described as frequencies and percent-
ages. Numeric variables were reported as the median and IQR. 
To compare dichotomous variables with interval or ordinal vari-
ables, the Mann-Whitney U test was performed. Correlations 
between two dichotomous variables, or dichotomous variables 
and nominal variables were assessed using the χ² or Fisher’s 
exact test. The Spearman’s rank correlation was performed to 
assess differences between two interval variables or between 
interval and ordinal variables.
The threshold for statistical significance was p<0.05. Statis-
tical analysis was performed with the IBM Statistical Package for 
the Social Sciences (SPSS) V.24.
resulTs
Patient inclusion and clinical classification criteria
In total, 337 patients were included from the Eurofever registry. 
Patients came from 30 different centres. Clinical information 
was available for 235 patients. See figure 1 for a detailed flow-
chart of included and excluded patients. Patients were excluded 
when inflammatory markers were not elevated during fever 
episodes (n=26) or no fever was reported (n=3). Additionally, 
one patient was excluded because he had a pathogenic mutation 
in the MEFV gene and had a positive clinical classification score 
for FMF, classifying him as FMF patient.10
When applying the Federici criteria, a majority of the patients 
(n=1364,9%) did not classify for any of the major periodic fever 
syndromes.10 Twenty-nine patients, coming from 10 centres, had 
a clinical picture consistent with a monogenetic SAID according 
to the Federici criteria, without genetic analysis having been 
performed on the associated gene.10 For these patients, a specific 
query was raised to the enrolling centres. Eleven patients had 
additional genetic analysis performed on the associated genes 
and turned out to be negative or not confirmatory. The other 
18 patients were excluded from analysis (figure 1). Four of them 
received an alternative diagnosis. In one patient, who clinically 
classified as MKD, additional genetic tests revealed pathogenic 
mutations in the MVK gene. The other three patients were 
diagnosed with diseases other than their clinical classification: 
systemic juvenile idiopathic arthritis (n=2) and ARPC1B-com-
bined immunodeficiency (n=1).
In total, 187 patients were included in this study. Fifty-four 
patients classified as clinically compatible with one or two hered-
itary periodic fever syndromes. In four of them, genetic variants 
were found in the associated genes (figure 2). These variants 
were not confirmatory of a defined SAID.
baseline characteristics
Patients came from 17 different countries (online supplementary 
table 1). Most patients came from Italy (n=103) and the Neth-
erlands (n=21). Almost half of the patients were female (49%). 
The median age at disease onset was 4.3 years (IQR 1.3–12.9) 
(figure 3A). Thirty-five patients had a disease onset in adulthood.
episode characteristics
Seven patients had a chronic disease course, 17 patients had a 
chronic disease course with recurrent acute exacerbations and 
163 patients had a disease course with recurrent episodes. 
copyright.
 on A












is: first published as 10.1136/annrheum




1407Ter Haar NM, et al. Ann Rheum Dis 2019;78:1405–1411. doi:10.1136/annrheumdis-2018-214472
Autoinflammatory disorders
Figure 1 Flowchart of included patients. Eurofever clinical classification criteria: Federici criteria for monogenetic SAID.10 *In five patients, no 
response was received from the centres, four patients received an alternative diagnosis (MKD, systemic juvenile idiopathic arthritis, ARPC1B-combined 
immunodeficiency), one patient died before additional genetic testing was performed and eight patients were lost at follow-up before additional 
genetic testing was performed. MKD, mevalonate kinase deficiency; SAID, systemic autoinflammatory disease.
Figure 2 Clinical classification criteria and genetic variants. This figure 
shows the classification of the 54 patients who fulfilled the clinical 
criteria for a hereditary periodic fever syndrome.10 Two of them scored 
positive for two syndromes: TRAPS and MKD, TRAPS and CAPS. The third 
column displays the number of patients in whom variants were found 
in the associated gene. * Variants found in the associated genes: FMF 
p.A744S; MKD p.T356M; TRAPS p.R92Q; n.=number of patients. CAPS, 
cryopyrin-associated periodic syndromes; MKD, mevalonate kinase 
deficiency; TRAPS, tumour necrosis factor-receptor-associated periodic 
syndrome.
Patients with recurrent episodes had a median of 12.0 episodes 
per year (IQR 5.0–14.5), with a median duration of 4.0 days 
(IQR 3.0–7.0) (figure 3B and C). An irregular disease pattern 
was more frequently seen than a regular disease pattern (55.6% 
vs 38.5%). A minority of patients (13.4%) reported specific trig-
gers for disease episodes, including emotional stress and infec-
tion (figure 3D). Clinical manifestations for patients with chronic 
and recurrent disease course are summarised in table 1. Most 
commonly reported symptoms were arthralgia, myalgia, abdom-
inal pain, fatigue, malaise and mucocutaneous manifestations.
Treatment response
Non-steroidal anti-inflammatory drugs (NSAIDs) and steroids 
were frequently used during attacks. NSAIDs were beneficial in 
80/105 patients, but were rarely completely effective. Steroids 
were beneficial in 85/104 patients (41 complete, 44 partial 
response). With colchicine therapy, 7/49 patients had a complete 
response and 22 had a partial response. Thirty patients used 
colchicine as maintenance therapy and 8 patients used colchi-
cine on demand (11 treatment schedule unknown). Thirteen 
patients got treated with anakinra, five had a complete response 
and three had a partial response. Four patients used anakinra 
as maintenance therapy and four patients used anakinra on 
demand (five treatment schedule unknown). Methotrexate was 
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Figure 3 Disease characteristics, medication response. Other triggers 
were teething (1), surgery (1), constipation (1), heat (1).
Table 1 Clinical manifestations during episodes
Chronic 
disease 
course (7) recurrent disease course patients (180)*
n (%)† n (%)† Always sometimes/often
Mucocutaneous 5 (71%) 123 (69%)
Aphthous stomatitis 1 (14%) 10 (6%) 43 (24%)
Erythematous 
pharyngitis
1 (14%) 5 (3%) 42 (23%)
Exudative pharyngitis 0 6 (3%) 27 (15%)
Maculopapular rash 4 (57%) 10 (6%) 25 (14%)
Gastrointestinal 2 (29%) 104 (58%)
Abdominal pain 2 (29%) 23 (13%) 64 (36%)
Vomiting 0 7 (4%) 37 (21%)
Diarrhoea 1 (14%) 2 (1%) 28 (16%)
Musculoskeletal 7 (100%) 118 (66%)
Arthralgia 6 (86%) 27 (15%) 80 (44%)
Myalgia 6 (86%) 17 (9%) 63 (35%)
Oligoarthritis 1 (14%) 2 12%) 10 (6%)
Ocular 1 (14%) 29 (16%)
Conjunctivitis 1 (14%) 0 17 (9%)
Periorbital oedema 0 1 (1%) 8 (4%)
lymphoid 5 (71%) 89 (49%)
Enlarged cervical lnn 1 (14%) 20 (11%) 56 (33%)
Hepatomegaly 1 (14%) 8 (4%) 13 (7%)
Splenomegaly 1 (14%) 6 (3%) 14 (8%)
Cardiorespiratory 2 (29%) 29 (16%)
Chest pain 1 (14%) 2 (1%) 19 (11%)
Pericarditis 1 (14%) 1 (1%) 9 (5%)
neurological 2 (29%) 74 (41%)
Headache 2 (29%) 22 (12%) 45 (25%)
Morning headache 0 3 (2%) 19 (11%)
Genito-urinary 0 13 (7%)
Urethritis/cystitis 0 0 6 (3%)
Gonadal pain 0 1 (1%) 2 (1%)
Constitutional 7 (100%) 179 (99%)
Fatigue 5 (71%) 33 (18%) 73 (41%)
Malaise 5 (71%) 34 (19%) 65 (36%)
Clinical manifestations of all patients, separated for patients with a chronic disease 
course and recurrent disease course. In grey: number of patients that reported 
at least one symptom of that organ system. In white: most commonly reported 
symptoms of that organ system. For patients with a recurrent disease course the 
separate symptoms are split into always (left column) or sometimes/often present 
during episodes (right column).
*Patients with recurrent disease course and chronic disease course with recurrent 
acute exacerbations.
†Percentage of total with chronic or recurrent disease course (7 or 180 patients).
lnn, lymph nodes; n, number of patients.
given in 10 patients, with a complete response in 2 and a partial 
response in 5 patients. Adenoidectomy and/or tonsillectomy had 
limited effect; 8/9 adenotonsillectomies, 1/1 tonsillectomies and 
1/2 adenoidectomies were ineffective. Figure 3E summarises the 
responses to treatment.
Comparing treatment response to other clinical information, 
we found that patients with a good response to colchicine had 
a shorter episode duration compared with poor responders 
(p=0.030). In addition, a regular pattern of febrile episodes was 
more often described in patients with a good response to steroids 
or colchicine (p=0.050 and p=0.002, respectively). Patients 
with a good response to anakinra had a lower episode frequency 
(p=0.037), were older at disease onset (p=0.018) and more 
often had an irregular disease pattern (p=0.018) compared with 
patients with a moderate or bad response to anakinra.
Family history
Twenty-four patients had affected relatives. In 12 patients, first 
degree relatives were affected. Three patients had multiple rela-
tives affected. Within our cohort, two patients were related to 
each other: two sisters from Italy with a disease onset at 1.0 year 
and 12.0–13.0 attacks/year with a duration of 3.0 days. Common 
features of these sisters were a recurrent disease course, exuda-
tive pharyngitis, bilateral enlarged cervical lymph nodes, fatigue 
and malaise.
Patients with relatives affected were significantly younger at 
disease onset (2.0 vs 5.8 years, p=0.007) and more often had a 
regular disease pattern (63.6% vs 31.5%, p=0.007) compared 
with patients without relatives affected. Furthermore, genetic 
variants were more often found in patients with relatives affected 
(27.3% vs 5.4%, p=0.005).
Genetic characteristics
Analysis of one or more SAID-related genes was performed 
in 159 patients (85.0%), either by complete gene screening, 
screening of most relevant exons or screening of most relevant 
point mutations. In total, 15 patients carried likely pathogenic 
variants or variants of uncertain significance. Two patients had 
a genetic variant in the NLRP3 gene, seven in the MEFV gene, 
two in the MVK gene, four in the TNFRSF1A gene and last, one 
patient had a variant in the NOD2 gene (table 2). No variants 
were reported in the PSTPIP1, NLRP12, ADA2 or IL1RN gene. 
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Table 2 Genetic characteristics
Molecular analyses
n.tested Complete gene screening Most relevant exons Most relevant point mutations Unknown n.variants found Variants Genetic class*














TNFRS1A 119 28 84 7 4 p.R92Q 3
MVK 79 40 28 1 10 2 p.T356M 3
NOD2 9 7 2 1 p.R702W/SNP8 3
NLRP12 6 3 1 2 0
PSTPIP1 3 1 2 0
ADA2 1 1 0
IL1RN 1 1 0
*Genetic classification: 3=uncertain significance, 4=likely pathogenic.
class, classification; n, number of patients.
Table 3 Distinctive manifestations in 46 patients
n. n.
Musculoskeletal 7 Gastrointestinal 6
  Bone alteration/deformity 5   Aseptic peritonitis 3
  Flexion contractures 3   Gastrointestinal ulcers 2
  Osteitis 2   Gastrointestinal bleeding 1
  Osteolytic lesions 2   Intestinal occlusion 1
  Muscular atrophy 3   Peritoneal adhesions 1
  Hyperostotic lesions 1   Gut perforation 1
neurological 21 Cardiorespiratory 15
  Seizures 10   Pericarditis 11
  Intellectual impairment 8   Venous thrombosis 1
  Aseptic meningitis 2   Arterial thrombosis 1
  Cranial neuropathy 3   Pulmonary fibrosis




  Peripheral neuropathy 1
  Hydrocephalus 2     
  Cerebellar syndrome 1     
Mucocutaneous 4 Ocular 1
  Genital ulcers 2   Retinal vasculitis 1
  Pyoderma gangrenosum 1 Other 1
  Necrotic lesions extremities 1   Macrophage activation syndrome 1
n, number of patients.
One patient had variants found in two genes, the p.R92Q variant 
in the TNFRSF1A gene and the p.V198M variant in the NLRP3 
gene.
distinctive manifestations
More distinctive manifestations were reported in 46 patients 
(table 3); most frequently reported were seizures (n=10), peri-
carditis (n=11), intellectual impairment (n=8) and bone alter-
ation/deformity (n=5). A detailed description for these more 
severely affected patients can be found in online supplementary 
table 2.
Two groups of patients stood out. First, patients with peri-
carditis (n=11) were older at disease onset (33.8 vs 4.0 years, 
p<0.001) and had a lower episode frequency (3.0 vs 12.0/year, 
p=0.001), which was more often reported as irregular (9/11 
vs 95/167, p=0.011). Patients with pericarditis often reported 
arthralgia (5/11), myalgia (5/11) and abdominal pain (3/11). In 
3/9 tested patients, genetic variants were found. The TNFRSF1A 
gene was screened in eight patients, in two patients, the p.R92Q 
variant was found. The MEFV gene was tested in seven patients; 
in one patient, the p.A744S variant was found, and he did not 
present a clinical phenotype consistent with FMF.
Second, patients with an intellectual impairment (n=8) were 
younger at disease onset (2.2 vs 4.7 years, p=0.034). Their 
median episode duration was 4.5 (3.0–6.3) days, they had a 
median of 12.0 (5.5–15.8) episodes per year and in 28.6% rela-
tives were affected, and this did not differ from other patients. 
The following symptoms were more frequently reported in 
patients with an intellectual impairment: abdominal pain (100% 
vs 46.9%, p=0.043), arthralgia (100% vs 59.5%, p=0.045), 
headache (87.5% vs 34.1%, p<0.001), seizures (28.6% vs 4.6%, 
p=0.050) and generalised lymph node enlargement (57.2% vs 
10.1%, p<0.001). Seven of these patients had genetic analyses 
performed (TNFRSF1A, n=5; MEFV, n=5; NLRP3, n=2; MVK, 
n=5; PSTPIP, n=1; ADA2, n=1), all without genetic variants 
found.
dIsCussIOn
We described a large well-defined cohort of patients with unde-
fined SAIDs, enabling us to provide a broad description of the 
clinical characteristics, the genetic characteristics and the treat-
ment response.
An advantage of our study is the standardised and elaborate 
list of symptoms, which yields a comprehensive clinical picture 
of the patients. In addition to fever, most commonly reported 
symptoms were: arthralgia, myalgia, abdominal pain, mucocu-
taneous manifestations, fatigue and malaise. Arthralgia, myalgia 
and mucocutaneous manifestations were frequently reported 
in other, smaller cohorts of patients with undefined periodic 
inflammation as well.14–18 Fatigue and malaise were reported by 
more than half of our patients, but were only mentioned in one 
other study.18 As fatigue and malaise are generally often encoun-
tered by patients with rheumatic diseases, an under-reporting 
of these symptoms in other cohorts seems to be the most likely 
explanation of this discrepancy.18 19 Most of our patients had a 
disease onset before the age of 5 years. However, even though 
a relevant number of patients with an adult-onset have been 
included, a selection bias could have decreased the average age 
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of onset, due to an over-representation of paediatric centres in 
the Eurofever project. In other studies, the age of disease onset 
varied from 4 to 43 years.14–18
As in most of the defined SAIDs, the majority of patients 
in our cohort had a favourable response to NSAIDs, steroids, 
colchicine and anakinra, but patients rarely achieved complete 
response with NSAIDs alone.20–23 Contrary to the good effect 
observed in PFAPA syndrome, tonsillectomy and/or adenoidec-
tomy were rarely effective in patients with undefined SAIDs.21 22 
Nonetheless, we cannot exclude a reporting bias, as physicians 
tend to enrol patients with a long-standing or difficult-to-treat 
disease course and thus leave out patients with a complete 
response to NSAIDs, tonsillectomy and/or adenoidectomy.
Looking at patients with distinctive manifestations, we found 
that patients with pericarditis, in line with published data 
concerning idiopathic recurrent pericarditis, had a disease onset 
in adulthood and a low episode frequency.24 However, patients 
with pericarditis in our cohort seem to form a specific cluster, 
since they also often suffered from musculoskeletal symptoms 
and abdominal pain, usually not reported in typical recurrent 
pericarditis.25 This could mean that these patients either display 
an extension of the spectrum of idiopathic recurrent pericarditis 
or they form a distinct entity. Second, patients with an intellec-
tual impairment often had relatives affected and were young at 
disease onset. Possibly these patients form a distinct entity on 
their own as well. Online supplementary table 2 can be used 
to identify similar patients in other centres with distinctive 
symptoms.
A limitation of our study is its retrospective design. As 
mentioned previously, we cannot exclude a bias in the selection 
of patients entered in the registry, favouring patients with more 
severe disease. An additional selection bias was introduced by 
the design of this analysis, excluding patients with normal acute 
phase proteins. Furthermore, for some patients, parts of the clin-
ical variables were missing as they were not retraceable from 
their clinical charts. More importantly, the lack of prospective 
follow-up data hampers conclusions regarding outcome and 
long-term therapy response in these patients. The treatment 
response was also difficult to interpret due to the possibility that 
the natural disease course or simultaneous use of other drugs 
influenced the response to therapy.21 To overcome these limita-
tions in future research, a follow-up registry has recently been 
implemented by the Eurofever working group.26
We have found a correlation between the presence of genetic 
variants and a positive family history of (undefined) SAIDs. 
Whether this represents a causal relation is uncertain. One might 
reason that these genetic variants, although not by themselves 
pathogenic, could contribute to autoinflammation in combina-
tion with environmental triggers or other (epi)genetic factors. 
However, there may be mere confounding by indication as 
patients with a positive family history might have been more 
likely to undergo genetic testing. Furthermore, the method of 
genetic screening varied among patients and this registry was 
not designed for in-depth analyses of family history nor disease 
aetiology. Laboratory experiments and population-based genetic 
studies are necessary to define a causal relation between genetic 
variants and autoinflammation.
One of the main limitations of this study is the lack of homo-
geneous and complete genetic analysis in the entire population 
of patients included in our study. Hence, genetic diagnoses 
might have been missed, because the relevant genes or the rele-
vant regions of the affected gene were not tested. In particular, 
genes that had not been identified as cause of autoinflamma-
tory disease when the registry started, like TNFAIP3 causing 
A20 haploinsufficiency, may not have been tested in patients 
with the relevant phenotype.27 Similarly, somatic mosaicism for 
autosomal dominant mutations would not have been detected. 
Genetic screening was often limited, due to the large geograph-
ical distribution of the enrolling centres and limited availability 
of molecular screening in some centres. Notably, most patients 
were enrolled from 2009 onwards, far before next generation 
sequencing of gene panels was routinely used. We tried to mini-
mise the chance of erroneously including patients with a well-de-
fined SAID, by excluding those with a clinical picture indicative 
of such a disease, but in whom the relevant genetic analysis had 
not been performed.
We want to stress the importance of thorough diagnostics. 
Many patients in our cohort classified positive with the Federici 
clinical score.10 This confirms the difficulty in differentiating 
between undefined and defined SAIDs on clinical grounds only 
and suggests a need for new classification criteria for monogenic 
autoinflammatory diseases, which should combine both genetic 
and clinical variables. The age of sequential single gene analysis 
is over. Patients with undefined SAIDs deserve next generation 
sequencing with gene panels and, if negative, to proceed to whole 
exome sequencing, where and when available and affordable.
In conclusion, we provide a detailed description of the clin-
ical characteristics of a large well-defined international cohort of 
patients with undefined SAIDs. This protean group of patients 
represents one of the most frequent subsets observed in the daily 
practice of autoinflammatory disease clinics.1 2 Despite the large 
variability of this heterogeneous group of patients, the avail-
ability of a relevant number of affected individuals allowed to 
identify some interesting clues. A relevant proportion of the 
patients had other affected family members. When available, 
a whole exome sequencing approach would be appropriate in 
such families in order to identify possible new genes. Moreover, 
some distinctive manifestations (like pericarditis or intellectual 
impairment) could allow the identification of novel SAID clinical 
clusters, possibly related to specific genes.
In this study, we described the characteristics of patients with 
undefined SAIDs as a single group. However, different under-
lying causes for autoinflammation are undoubtedly present in 
this cohort. Future research, combining extensive genetic data 
with functional and phenotypic data, is likely to provide insight 
into genotype-phenotype relation, leading to the eventual iden-
tification of new SAIDs within this group.28
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